2021
The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer
Wang Z, Xiao R, Huang J, Qin X, Hu D, Guo E, Liu C, Lu F, You L, Sun C, Chen G. The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer. Microbial Ecology 2021, 84: 302-313. PMID: 34405250, DOI: 10.1007/s00248-021-01800-0.Peer-Reviewed Original ResearchConceptsLocally advanced cervical cancerLocally advanced cervical cancer patientsPlatinum-based chemotherapy responseAdvanced cervical cancerCervical cancerChemotherapy responseAlpha diversityVaginal microbiotaVaginal samplesCC patientsVaginal microbiomeHealthy controlsPredicting neoadjuvant chemotherapy responsePlatinum-resistant patientsNeoadjuvant chemotherapy responseAssociated with platinum-based chemotherapy responseCervical cancer patientsVaginal microbiota diversityNeoadjuvant chemotherapyHPV infectionBeta diversityBacteroides genusChemotherapy effectCancer patientsBacteroides abundanceFecal microbiota transplantation mitigates vaginal atrophy in ovariectomized mice
Huang J, Shan W, Li F, Wang Z, Cheng J, Lu F, Guo E, Beejadhursing R, Xiao R, Liu C, Yang B, Li X, Fu Y, Xi L, Wang S, Ma D, Chen G, Sun C. Fecal microbiota transplantation mitigates vaginal atrophy in ovariectomized mice. Aging 2021, 13: 7589-7607. PMID: 33658399, PMCID: PMC7993734, DOI: 10.18632/aging.202627.Peer-Reviewed Original ResearchConceptsVulvovaginal atrophyFecal microbiota transplantationOvarian functionFemale miceMicrobiota transplantationGut microbiotaVagina of miceMenopause-related symptomsVaginal atrophyEpithelial atrophyHormone therapyEstrogen deficiencyVaginal cellsOvariectomized miceOvariectomized onesVaginal healthFollow-upOld miceCancer patientsAlternative treatmentVaginaMiceModulating gut microbiotaOlder womenAtrophy
2020
Six Gynecological Cancer Patients Infected With SARS-CoV-2 After Surgery or Radio-/Chemo-Therapy Treatment: Case Series
Liu C, Huang Y, Qin T, Guo E, Wu P, Sun C, Chen G. Six Gynecological Cancer Patients Infected With SARS-CoV-2 After Surgery or Radio-/Chemo-Therapy Treatment: Case Series. Frontiers In Oncology 2020, 10: 1606. PMID: 33042803, PMCID: PMC7522534, DOI: 10.3389/fonc.2020.01606.Peer-Reviewed Original ResearchTreatment of gynecological cancer patientsGynecologic cancer patientsCancer patientsSARS-CoV-2History of cancer treatmentTreatment historyLow immune stateRaised white blood cellNosocomial SARS-CoV-2 infectionDifficulty of diagnosisCancer treatment historySARS-CoV-2 infectionWhite blood cellsDiagnosis of COVID-19Symptoms of COVID-19Antiviral treatmentAtypical symptomsAuxiliary examinationsTongji HospitalTreatment of COVID-19Treatment planningImmune stateCancer-related treatmentPatientsCancer treatmentKras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesT-Lymphocytes, RegulatoryTime FactorsConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stage
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)
LIU C, CHEN R, CHEN Y, FU D, HONG D, HAO J, LIU D, LI J, LI S, LI Y, MAI G, MOU Y, NI Q, PENG L, QIAN H, QIN R, SUN B, SHAO C, SUN Y, TIAN B, WANG J, WANG W, WANG W, ZHAO G, YU X. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). International Journal Of Oncology 2015, 47: 1512-1516. PMID: 26314752, DOI: 10.3892/ijo.2015.3128.Peer-Reviewed Original ResearchConceptsPara-aortic lymph nodesPancreatic head cancerHead cancerCurative surgeryChinese Study GroupLymph nodesStandard lymphadenectomyPancreatic cancerResectable pancreatic head cancerStudy groupCases of pancreatic head cancerHigh-volume centersPancreatic cancer patientsResection statusTumor burdenPrimary tumorResected casesNode stationsPoor prognosisCancer casesCancer patientsDorsal pancreasConsensus statementSurgeryCancerMetabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring treatment responsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2011
Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models
Ogunwobi O, Liu C. Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models. Critical Reviews In Oncology/Hematology 2011, 83: 319-328. PMID: 22178416, DOI: 10.1016/j.critrevonc.2011.11.007.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionHepatocellular carcinomaHepatic metastasesPrognostic importanceExperimental modelColon cancerTreatment of patientsRole of EMTHuman cancer patientsPotential therapeutic targetHuman malignant diseaseSignificant morbidityCancer patientsMalignant diseaseMalignant conditionsLiver cancerTherapeutic targetBasic scientistsCancerFurther studiesPatientsCarcinomaMetastasisLiverHuman tissuesKinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
Cao M, Xu Y, Youn J, Cabrera R, Zhang X, Gabrilovich D, Nelson D, Liu C. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Laboratory Investigation 2011, 91: 598-608. PMID: 21321535, PMCID: PMC3711234, DOI: 10.1038/labinvest.2010.205.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzenesulfonatesBone Marrow CellsCarcinoma, HepatocellularCell DivisionCell Line, TumorDisease ProgressionImmunity, CellularLiver NeoplasmsMiceMice, Inbred BALB CMyeloid CellsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsPyridinesSorafenibSpleenT-Lymphocytes, RegulatoryConceptsMyeloid-derived suppressor cellsImmunosuppressive cell populationsAnti-tumor immunityTumor-bearing hostsImmune cell populationsLiver cancer modelMurine liver cancer modelHepatocellular carcinomaCell populationsCancer modelNovel multi-kinase inhibitorSuppressive immune cell populationBALB/c miceDepletion of TregsImpact of sorafenibRegulatory T cellsAdvanced hepatocellular carcinomaTreatment of sorafenibKinase inhibitor sorafenibMulti-kinase inhibitorHCC cell growthSuppressor cellsTumor burdenC miceCancer patients
2007
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson D. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells. Laboratory Investigation 2007, 87: 582-590. PMID: 17372588, DOI: 10.1038/labinvest.3700540.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsRegulatory T cellsT cell proliferationT cellsCancer patientsControl peripheral blood mononuclear cellsDepletion of TregsAntigen-reactive lymphocytesTumor-related factorsBlood mononuclear cellsHepatocellular carcinoma patientsT cell populationsHost immune systemCell linesSuppressor abilityHCC cell linesHuman hepatoma cell lineAntitumor immunityCarcinoma patientsTumor burdenFoxp3 expressionMononuclear cellsCTLA-4Reactive lymphocytesTregs
2006
An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens
Wang B, He J, Liu C, Chang L. An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006, 24: 3477-3489. PMID: 16530303, PMCID: PMC1850619, DOI: 10.1016/j.vaccine.2006.02.025.Peer-Reviewed Original ResearchConceptsTumor-associated antigensDendritic cellsModification of DCsMultiple tumor-associated antigensStrong anti-tumor responsesReactive dendritic cellsAnti-tumor responseT cell responsesLentiviral vectorsCancer-specific antigensCell antigen 2Tumor-bearing miceThymidine kinase suicide geneDC vaccinesVaccine modalitiesCancer immunotherapyCancer patientsTherapeutic injectionsTherapeutic effectExtended survivalAntigen 2Danger signalsVivo eliminationCell responsesTherapeutic potential